NK cell therapy: Targeting disease relapse after hematopoietic stem cell transplantation

Immunotherapy

Volumn 4, Issue 3, 2012, Pages 305-313

  Farhan, Shatha ^a   Lee, Dean A ^a   Champlin, Richard E ^a   Ciurea, Stefan O ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

cellular therapy; haploidentical stem cell transplantation; NK cell expansion; NK cells

Indexed keywords

ALEMTUZUMAB; CD16 ANTIGEN; CD56 ANTIGEN; CD94 ANTIGEN; CYCLOSPORIN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; STAT3 PROTEIN; STEROID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOIMMUNITY; ANTIGEN PRESENTING CELL; CELL DIFFERENTIATION; CELL EXPANSION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL STUDY; EX VIVO STUDY; FEASIBILITY STUDY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; IMMUNOTHERAPY; INFUSION; LEUKAPHERESIS; LYMPHOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; REMISSION; REVIEW; SOLID TUMOR; T CELL DEPLETION; TREATMENT FAILURE;

ANIMALS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LYMPHOCYTE TRANSFUSION; RECURRENCE; TISSUE THERAPY;

EID: 84863391975     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.174     Document Type: Review

References (46)

1. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol. 9(8), 568-580 (2009).
2. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 22(11), 633-640 (2001). (Pubitemid 33043908)
3. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 47, 187-376 (1989). (Pubitemid 20010960)
4. Browne KA, Blink E, Sutton VR, Froelich CJ, Jans DA, Trapani JA. Cytosolic delivery of granzyme B by bacterial toxins: evidence that endosomal disruption, in addition to transmembrane pore formation, is an important function of perforin. Mol. Cell. Biol. 19(12), 8604-8615 (1999). (Pubitemid 30414053)
5. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J .Exp. Med. 188(12), 2375-2380 (1998). (Pubitemid 29028510)
6. Fehniger TA, Cooper MA, Nuovo GJ, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101(8), 3052-3057 (2003). (Pubitemid 36857995)
7. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J. Immunol. 143(10), 3183-3191 (1989). (Pubitemid 20010143)
8. Nagler A, Lanier LL, Phillips JH. Constitutive expression of high affinity interleukin 2 receptors on human CD16- natural killer cells in vivo. J .Exp. Med. 171(5), 1527-1533 (1990). (Pubitemid 20167548)
9. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97(10), 3146-3151 (2001).
10. Freud AG, Becknell B, Roychowdhury S, et al. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 22(3), 295-304 (2005). (Pubitemid 40387472)
11. Chan A, Hong DL, Atzberger A, et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J. Immunol. 179(1), 89-94 (2007). (Pubitemid 46986521)
12. Lanier LL. NK cell receptors. Annu. Rev. Immunol. 16, 359-393 (1998). (Pubitemid 28183369)
13. Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol. Today 21(5), 228-234 (2000). (Pubitemid 30259028)
14. Ljunggren HG, Karre K. In search of the 'missing self ': MHC molecules and NK cell recognition. Immunol. Today 11(7), 237-244 (1990). (Pubitemid 20198988)
15. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 20(3), 123-137 (2006). (Pubitemid 43786166)
16. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562), 2097-2100 (2002). (Pubitemid 34229476)
17. Santourlidis S, Trompeter HI, Weinhold S, et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J. Immunol. 169(8), 4253-4261 (2002). (Pubitemid 35178197)
18. Torkar M, Norgate Z, Colonna M, Trowsdale J, Wilson MJ. Isotypic variation of novel immunoglobulin-like transcript/ killer cell inhibitory receptor loci in the leukocyte receptor complex. Eur. J. Immunol. 28(12), 3959-3967 (1998). (Pubitemid 28558626)
19. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J. Immunol. 172(1), 644-650 (2004). (Pubitemid 38020523)
20. Gagne K, Brizard G, Gueglio B, et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum. Immunol. 63(4), 271-280 (2002). (Pubitemid 34303697)
21. Mcqueen KL, Dorighi KM, Guethlein LA, Wong R, Sanjanwala B, Parham P. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum. Immunol. 68(5), 309-323 (2007). (Pubitemid 46616984)
22. Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J. Intern. Med. 266(2), 154-181 (2009).
23. Shimizu M, Fontana A, Takeda Y, Yagita H, Yoshimoto T, Matsuzawa A. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. J. Immunol. 162(12), 7350-7357 (1999). (Pubitemid 29277711)
24. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8), 3051-3057 (2005).
25. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 17(19), 6287-6297 (2011).
26. Koehl U, Sorensen J, Esser R, et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol. Dis. 33(3), 261-266 (2004). (Pubitemid 39446496)
27. Barkholt L, Alici E, Conrad R, et al. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study. Immunotherapy 1(5), 753-764 (2009).
28. Boissel L, Tuncer HH, Betancur M, Wolfberg A, Klingemann H. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol. Blood Marrow Transplant. 14(9), 1031-1038 (2008).
29. Harada H, Saijo K, Watanabe S, et al. Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT. Jpn. J. Cancer Res. 93(3), 313-319 (2002). (Pubitemid 34464368)
30. Fujisaki H, Kakuda H, Imai C, Mullighan CG, Campana D. Replicative potential of human natural killer cells. Br. J. Haematol. 145(5), 606-613 (2009).
31. Somanchi SS, Senyukov VV, Denman CJ, Lee DA. Expansion, purification, and functional assessment of human peripheral blood NK cells. J. Vis. Exp. 48, 2540 (2011).
32. Denman CJ, Senyukov VV, Somanchi SS, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 7, e30264 (2012).
33. Cho D, Campana D. Expansion and activation of natural killer cells for cancer immunotherapy. Korean J. Lab. Med. 29(2), 89-96 (2009).
34. Gill S, Olson JA, Negrin RS. Natural killer cells in allogeneic transplantation: effect on engraftment, graft-versus-tumor, and graft-versus-host responses. Biol. Blood Marrow Transplant. 15(7), 765-776 (2009).
35. Kim DH, Sohn SK, Lee NY, et al. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors. Eur. J. Haematol. 75(4), 299-308 (2005). (Pubitemid 41297606)
36. Meller B, Frohn C, Brand JM, et al. Monitoring of a new approach of immunotherapy with allogenic (111) In-labelled NK cells in patients with renal cell carcinoma. Eur. J. Nucl. Med. Mol. Imaging 31(3), 403-407 (2004). (Pubitemid 38314085)
37. Meier R, Piert M, Piontek G, et al. Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors. Nucl. Med. Biol. 35(5), 579-588 (2008).
38. Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors. Immunol. Rev. 222, 70-100 (2008). (Pubitemid 351430365)
39. Koehl U, Srensen J, Esser R, et al. Immunotherapy with highly purified CD56+CD3- natural killer cells for paediatric patients after haploidentical stem cell transplantation. Presented at: 32nd Annual Meeting of the European Group for Blood and Marrow Transplantation. Hamburg, Germany, 19-22 March 2006.
40. Passweg JR, Tichelli A, Meyer-Monard S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 18(11), 1835-1838 (2004). (Pubitemid 39530014)
41. Passweg JR, Koehl U, Uharek L, Meyer-Monard S, Tichelli A. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. Best Pract. Res. Clin. Haematol. 19(4), 811-824 (2006). (Pubitemid 44424290)
42. Slavin S, Morecki S, Shapira MY, et al. Use of matched or mismatched rIL-2 activated donor lymphocytes positively selected for CD56+ for immunotherapy of resistant leukemia after allogeneic stem cell transplantation. J. Clin. Oncol. ASCO Annual Meeting Proceedings 22(14S), Abstract 6516 (2004).
43. Uharek L, Friedrichs B, Nogai A, et al. Successful treatment of high-risk and refractory acute myeloid leukemia with haploidentical stem cell transplantation plus NK cell therapy. Blood (ASH Annual Meeting Abstracts) 116(21), Abstract 2370 (2010).
44. Rizzieri DA, Storms R, Chen DF, et al. Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 16(8), 1107-1114 (2010).
45. Champlin R, Lee DA, Fernandez-Vina M, et al. Alloreactive NK cells to augment antileukemia cytotoxicity with allogeneic stem cell transplantation for AML/MDS: a Phase I study. Blood (ASH Annual Meeting Abstracts) 116(21), Abstract 489 (2010).
46. The Immuno Polymorphism Database - KIR Database. www.ebi.ac.uk/ipd/kir/ genes.html (Accessed 20 September 2011)